Dihydropyridine calcium-channel-blockers (DCCBs), used to treat high blood pressure, could speed up the progression of kidney ...
"ADA26: Kidney disease analysis given spotlight" was originally created and published by Clinical Trials Arena, a GlobalData ...
HealthDay on MSN
ERA: Dihydropyridine calcium-channel-blockers tied to higher risk for kidney disease progression in T2D
For adults with type 2 diabetes receiving guideline-directed renin-angiotensin inhibitors (RASi) and sodium-glucose ...
Six women aged 20–27 developed kidney-related complications after C-section deliveries at Bikaner’s PBM Hospital and are now ...
Program aims to improve diagnosis, support disease management and help people living with focal segmental glomerulosclerosis (FSGS) better understand available treatment options ...
The thresholds for kidney function currently used to diagnose chronic kidney disease (CKD) reflect a true increase in the ...
The drug finerenone significantly slows the decline in kidney function in patients with chronic kidney disease (CKD) who do ...
Managing mental and emotional health is a key part of managing chronic kidney disease.
Significant underdiagnosis of chronic kidney disease (CKD), now the ninth leading cause of death globally, is endangering ...
For adults with type 2 diabetes receiving guideline-directed renin-angiotensin inhibitors (RASi) and sodium-glucose cotransporter-2 inhibitors (SGLT2i), dihydropyridine calcium-channel-blocker (DCCB) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results